TH1 Dendritic Cell Immunotherapy

· MD Anderson Cancer Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TH1 Dendritic Cell Immunotherapy, covering 2026-02-13 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma [Phase 1]